1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The Fiscal Year 2015 (FY15) Joint Program Committee 8/Clinical and Rehabilitative Medicine Research Program (JPC-8/CRMRP) Extremity Regeneration Technology/Therapeutic Development Award (ERTTDA) is intended to support the translation of promising preclinical findings into products focused on extremity regeneration. The focus is on bone and soft tissue reconstruction, limb and tissue salvage technologies, and regenerative medicine technologies for the treatment of trauma-induced damage. All products in development should be responsive to the health care needs of military Service members, Veterans, and other Military Health System beneficiaries, as well as the general public. All applications must specifically and clearly address the military relevance of the proposed research.The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product such as clinical guidance for standard of care. The Principal Investigator (PI) must provide a transition plan (including potential funding and resources) showing how the product will progress to the next level of development (e.g., clinical trials, delivery to the military or civilian market) after the completion of the award.Proof-of-concept demonstrating the potential utility of the proposed product, or a prototype/preliminary version of the proposed product, should already be established. Applicants must include relevant data that support the rationale for the proposed study. These data may be unpublished and/or from the published literature.Examples of the types of research that may be supported include, but are not limited to: Developing and validating clinical guidance/guidelines for standard of care; Testing new therapeutic modalities (agents, delivery systems, and chemical modification of lead compounds) using established or validated preclinical systems; Designing and implementing pilot or full-scale Good Manufacturing Practice (GMP) production of therapeutics and/or delivery systems for use in advanced preclinical and initial clinical trials; Developing pharmacologic agents through absorption, distribution, metabolism, excretion, and toxicity (ADMET) studies;Developing pharmacologic agents to Investigational New Drug (IND) stage for initiation of Phase I clinical trials; Developing prototype devices to Investigational Device Exemption (IDE) stage for initiation of clinical trials; Optimizing diagnostic or treatment devices for field deploymentTo meet the intent of the FY15 JPC-8/CRMRP ERTTDA, applicants must specifically address one or both of the Focus Areas listed below; (1) Treatments of soft tissue injury, specifically, nerve, muscle, and vascular injury to the extremities. The aim of these technologies is to: (a) maintain the structure and function of denervated end organs distal to a nerve injury; (b) restore functional muscle tissue; and (c) restore vascular perfusion. Both innovative definitive care solutions as well as innovative technologies that may better enable a definitive care solution to be delivered at some future time point, such as vascular shunting or stenting technologies, will be considered; (2) Treatments for bone healing, for example, technologies that create a wound environment more conducive to bone healing following injury to the extremities.
Funding Opportunity Number: W81XWH-15-DMRDP-CRMRP-ERTTDA. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $6.3M total program funding.
Get alerted about grants like this
Save a search for “Dept. of the Army -- USAMRAA” or related topics and get emailed when new opportunities appear.
Search similar grants →Based on current listing details, eligibility includes: Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $6.3M total program funding Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is December 22, 2015. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
The Combat Casualty Care Research Program (CCCRP) provides resources for advances in biotechnology research administered by the Telemedicine and Advanced Technology Research Center (TATRC), located at Fort Detrick, Maryland. TATRC facilitates interdisciplinary research partnerships led by industry (that may also include academia and government) that advance the development of emerging technologies and improvements in health care. With this Program Announcement/Funding Opportunity, the US Army Medical Research and Materiel Command (USAMRMC) is seeking to fund biotechnology research that culminates in outcomes and products that may qualify as advanced development activities within the Department of Defense (DoD). The results of this research will support medical protection and treatment requirements and needs by leveraging the skills and talents of US based businesses and teaching-research academic institutions. The intent is to create enduring initiatives and collaborations that will develop and support sustained business and enterprise solutions. The results of the research funded through this Program Announcement/Funding Opportunity are expected to increase the body of knowledge available to professionals and practitioners in health, medical science and related fields. The research impact is expected to benefit both civilian and military communities, particularly as it relates to the topic area of prehospital use of plasma for traumatic hemorrhage. Funding Opportunity Number: W81XWH-11-PUPTH-IIA. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: Up to $8M per award.
The FY13 PH/TBI Research Program TBI Endpoints Development (TED) Award mechanism supports the establishment of a collaborative, multidisciplinary research team to advance endpoints for use in trials involving diagnosis and treatment of mild to moderate TBI (mTBI to modTBI). While a number of potentially useful endpoints for mTBI to modTBI diagnostics and therapeutics exist, a majority of them have not been validated and qualified for use as a reference measure of diagnostic or therapeutic effectiveness. The TED research team will address a critical need within the TBI research community by developing clinically relevant endpoints that can support regulatory approvals and be applicable for use in research tests and clinical trials. The goal is to improve diagnosis, treatment, and rehabilitation strategies for mTBI to mod TBI. This award is not intended to support the direct development of new TBI therapeutic or diagnostic agents and/or devices. Funding Opportunity Number: W81XWH-13-PHTBI-TED. Assistance Listing: 12.420. Funding Instrument: CA. Category: ST. Award Amount: $17M total program funding.
The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome. Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Two different funding levels, based on the scope of the research, are available under this Program Announcement/Funding Opportunity. Funding Levels 3 and 4 are available under a different Program Announcement (W81XWH-14-BCRP-BREAKTHROUGH2_FL34). It is the responsibility of the Principal Investigator (PI) to select the funding level that is most appropriate for the research proposed. The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level: Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development. Research with potential to yield new avenues of investigation. Proof of concept. No preliminary data required. Funding Level 2: Research that is already supported by preliminary data and has potential to make significant advancements toward clinical translation. Demonstration of efficacy in in vivo models, as applicable. Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive collaborations between investigators. The Partnering PI Option is structured to accommodate two PIs, called the Initiating PI and the Partnering PI, each of whom will receive a separate award. The Initiating and Partnering PIs have different submission requirements; however, both PIs should contribute significantly to the development of the proposed research project including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. New collaborations are encouraged, but not required. It is the responsibility of the PIs to describe how their combined expertise will better address the research question and explain why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly addressing distinct research questions. Funding Opportunity Number: W81XWH-14-BCRP-BREAKTHROUGH2-FL12. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $25M total program funding.